Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
CNS Depressants: Alcohol and Nicotine01:27

CNS Depressants: Alcohol and Nicotine

Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
Depressants01:28

Depressants

Depressant drugs, including alcohol and sedative-hypnotics, diminish central nervous system activity by enhancing the action of gamma-aminobutyric acid (GABA), a neurotransmitter that reduces brain activity and promotes relaxation. These substances can have various therapeutic uses but also pose significant risks, especially when misused or combined.
Alcohol is a common depressant that can induce a sense of relaxation and reduced inhibition at low doses. Contrary to its occasional...
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrated Psychosomatic Care in General Hospital Medicine: An Observational Study of Outcomes in Medically Complex Inpatients.

Journal of the Academy of Consultation-Liaison Psychiatry·2026
Same author

[White paper: a future vision for cross-sector integrated urological care].

Urologie (Heidelberg, Germany)·2026
Same author

Nucleation of α-pinene oxidation products with sulfuric acid.

Environmental science: atmospheres·2026
Same author

Role of methanesulfonic acid in atmospheric particle nucleation and growth.

Nature·2026
Same author

Percutaneous Intervention in External Outflow Graft Obstruction of Magnetically Levitated Left Ventricular Assist Device: Long-Term Follow-Up and Quality of Life.

Artificial organs·2026
Same author

Hemophagocytic lymphohistiocytosis in HIV-related lymphomas: a multicentre retrospective cohort study.

Leukemia·2026

Related Experiment Video

Updated: May 23, 2026

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training
07:50

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training

Published on: January 29, 2017

Dihydrocodeine/Agonists for alcohol dependents.

Albrecht Ulmer1, Markus Müller, Bernhard Frietsch

  • 1Gemeinschaftspraxis Dres.med. Ulmer, Frietsch, Mueller Stuttgart, Germany.

Frontiers in Psychiatry
|April 4, 2012
PubMed
Summary
This summary is machine-generated.

This study explored long-term treatment for alcohol addiction using agonist substances like Dihydrocodeine (DHC). A significant portion of patients showed improved health and reduced need for detoxifications, suggesting a viable treatment approach.

Keywords:
alcohol addictiondihydrocodeine

More Related Videos

The Motivation for Alcohol Reward: Predictors of Progressive-Ratio Intravenous Alcohol Self-Administration in Humans
05:40

The Motivation for Alcohol Reward: Predictors of Progressive-Ratio Intravenous Alcohol Self-Administration in Humans

Published on: April 28, 2022

A Prediction Error-driven Retrieval Procedure for Destabilizing and Rewriting Maladaptive Reward Memories in Hazardous Drinkers
08:05

A Prediction Error-driven Retrieval Procedure for Destabilizing and Rewriting Maladaptive Reward Memories in Hazardous Drinkers

Published on: January 5, 2018

Related Experiment Videos

Last Updated: May 23, 2026

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training
07:50

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training

Published on: January 29, 2017

The Motivation for Alcohol Reward: Predictors of Progressive-Ratio Intravenous Alcohol Self-Administration in Humans
05:40

The Motivation for Alcohol Reward: Predictors of Progressive-Ratio Intravenous Alcohol Self-Administration in Humans

Published on: April 28, 2022

A Prediction Error-driven Retrieval Procedure for Destabilizing and Rewriting Maladaptive Reward Memories in Hazardous Drinkers
08:05

A Prediction Error-driven Retrieval Procedure for Destabilizing and Rewriting Maladaptive Reward Memories in Hazardous Drinkers

Published on: January 5, 2018

Area of Science:

  • Addiction Medicine
  • Pharmacotherapy
  • Chronic Disease Management

Background:

  • Alcohol addiction is a chronic disease often inadequately treated, lacking comparable basic treatments to other severe chronic conditions.
  • Patients with repeated relapses or inability to achieve abstinence require long-term medication, potentially agonist substances.
  • A need exists for sustained therapeutic strategies for individuals with severe, persistent alcohol use disorder.

Purpose of the Study:

  • To present a best-practice approach for managing alcohol addiction using agonist substances.
  • To evaluate the efficacy of Dihydrocodeine (DHC) and other substances in a cohort of heavily alcohol-addicted patients.
  • To explore a new treatment setting and attitude for long-term alcohol addiction management.

Main Methods:

  • A retrospective analysis of 102 heavily alcohol-addicted patients treated since 1997 with Dihydrocodeine (DHC) as a primary focus.
  • Inclusion of other substances such as Buprenorphine, Clomethiazole, Baclofen, and Amphetamine based on individual patient needs.
  • Documentation of prior medically assisted detoxifications and therapies for the patient cohort.

Main Results:

  • Patients treated with DHC had a 4-year retention rate of 26.4%, with 2.8% successfully terminating treatment.
  • Significant improvement observed in clinical impression (mean 3.7 to 8.4) and a 65.5% reduction in the need for medically assisted detoxifications over 2 years.
  • Mean GGT levels improved from 206.6 U/l to 66.8 U/l after 2 years, indicating positive physiological changes.

Conclusions:

  • The study presents a novel approach to alcohol addiction treatment, involving specific substances, a unique setting, and a trusting patient-provider relationship.
  • Approximately one-quarter of patients achieved a stable, long-term positive status, comparable to findings with GHB and Baclofen in Italian studies.
  • Further optimizations in this treatment paradigm are possible, offering hope for improved long-term outcomes in alcohol addiction.